{"entity":{"id":"paper-mirasol-nejm-2023","kind":"paper","name":"MIRASOL: mirvetuximab soravtansine versus chemotherapy in folate receptor alpha-high platinum-resistant ovarian cancer","aka":[],"tldr":"The antibody-drug conjugate mirvetuximab soravtansine lengthened survival compared with chemotherapy in platinum-resistant ovarian cancer with high folate receptor alpha expression, the first drug ever to do so in this setting.","summary":"Phase 3 trial of 453 patients with platinum-resistant high-grade serous ovarian cancer, folate receptor alpha-high tumours and one to three prior regimens, randomised to mirvetuximab soravtansine or investigator's choice chemotherapy (paclitaxel, pegylated liposomal doxorubicin or topotecan).\n\nMedian progression-free survival was 5.62 versus 3.98 months (hazard ratio 0.65), objective response 42.3 versus 15.9 percent and median overall survival 16.46 versus 12.75 months (hazard ratio 0.67); ocular toxicity was frequent but mostly low grade.","asOf":"2026-09-17","links":[{"label":"N Engl J Med 2023","url":"https://doi.org/10.1056/NEJMoa2309169"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/38055253/"}],"tags":[],"related":[],"cancers":["platinum-resistant-ovarian-cancer","high-grade-serous-ovarian-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":["mirvetuximab-soravtansine"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["mirasol"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":["nejm"],"dependsOn":[],"notes":[],"journal":"New England Journal of Medicine","year":2023,"doi":"10.1056/NEJMoa2309169","pmid":"38055253","authors":"Moore KN, Angelergues A, Konecny GE, et al.","paperType":"rct","findings":["Median overall survival 16.46 vs 12.75 months; hazard ratio 0.67.","Objective response 42.3 percent vs 15.9 percent."],"whatItMeans":"Folate receptor alpha testing is now standard in platinum-resistant ovarian cancer and mirvetuximab is the preferred treatment for high-expressing tumours, with an eye-care protocol.","caveats":["Only about 35 to 40 percent of tumours are folate receptor alpha-high.","Blurred vision and keratopathy require ophthalmic monitoring."],"changedPractice":true,"participants":453},"route":"/key-papers/paper-mirasol-nejm-2023/","neighbours":{"cancer":[{"id":"high-grade-serous-ovarian-cancer","kind":"cancer","name":"High-grade serous ovarian cancer","route":"/cancers/high-grade-serous-ovarian-cancer/"},{"id":"platinum-resistant-ovarian-cancer","kind":"cancer","name":"Platinum-resistant ovarian cancer","route":"/cancers/platinum-resistant-ovarian-cancer/"}],"drug":[{"id":"mirvetuximab-soravtansine","kind":"drug","name":"Mirvetuximab soravtansine","route":"/drugs/mirvetuximab-soravtansine/"}],"trial":[{"id":"mirasol","kind":"trial","name":"MIRASOL / GOG-3045","route":"/trials/mirasol/"}],"journal":[{"id":"nejm","kind":"journal","name":"New England Journal of Medicine","route":"/journals/nejm/"}]}}